Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

STUDY AND PROTOCOL NUMBER

RAISE XT

RA101495-02-302

STUDY DETAILS

The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.

FURTHER INFORMATION

ClinicalTrials.gov Identifier: NCT04225871

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis